The latest Ocugen narrative keeps the fair value estimate anchored at US$9.00, while only making very small tweaks to inputs ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
In recent days, Ocugen Inc has returned to the spotlight as a speculative biotech, with intense social media attention ...
(Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the publication of positive Phase 1 GARDian1 trial results for ...
Zacks Investment Research on MSN
Ocugen stock surges 75% year to date: What's in store for 2026?
Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocugen ...
Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
4d
Ocugen (OCGN) Valuation Check As Social Media Speculation Lifts Interest In Gene Therapy Prospects
The latest spike in social media attention around Ocugen (OCGN) and its eye disease and gene therapy pipeline has pushed the ...
A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...
Shares of Ocugen Inc. OCGN advanced 6.21% to $1.54 Tuesday, on what proved to be an all-around positive trading session for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback